OBM Transplantation (ISSN 2577-5820) is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc., which covers all evidence-based scientific studies related to transplantation, including: transplantation procedures and the maintenance of transplanted tissues or organs; assimilation of grafted tissue and the reconstitution of removed organs or parts of organs; transplantation of heart, lung, kidney, liver, pancreatic islets and bone marrow, etc. Areas related to clinical and experimental transplantation are also of interest.

OBM Transplantation is committed to rapid review and publication, and we aim at serving the international transplant community with high accessibility as well as relevant and high quality content.

We welcome original clinical studies as well as basic science, reviews, short reports/rapid communications, case reports, opinions, technical notes, book reviews as well as letters to the editor. 


Publication Speed (median values for papers published in 2023): Submission to First Decision: 6.7 weeks; Submission to Acceptance: 14.4 weeks; Acceptance to Publication: 6 days (1-2 days of FREE language polishing included)

Current Issue: 2024  Archive: 2023 2022 2021 2020 2019 2018 2017

Special Issue

Allogeneic Stem Cell Transplantation in Fanconi Anemia

Submission Deadline: June 30, 2024 (Open) Submit Now

Guest Editor

Lamia Torjemane, PhD, Associate Professor

Hematology and Adult Transplant Service, National Bone Marrow Transplant Center, 1006, Tunis, Tunisia


Research Interests: Topics related to hematopoietic stem cell transplant

About This Topic

Allogeneic hematopoietic stem cell transplantation (alloHCT) is the only curative treatment of bone marrow failure (BMF) and hematologic complications of Fanconi anemia (FA). However, the intrinsic FA DNA-repair defect complicates alloHCT, because of reliance on alkylating agents and radiation in conditioning regimen, as well as increased of graft failure and graft-versus-host disease (GVHD). Our previous results during the first 10 years, with low-dose cyclophosphamide and busulfan as conditioning, we previously reported early graft failure (18%) and acute GVHD and chronic GVHD occurred in 23% and 13% of patients respectively.[1] Since 2005, we opted for a Fludarabine-based conditioning regimen ± rabbit antithymocyte globin (ATG).[2] The incidence of acute GVHD decreased to 12.5%. Graft failure was later, between 3 and 5 years, with lower incidence (8%). Long-term overall survival reached 82% at 10 years. However, the evolution remains affected by the risk of clonal evolution (acute leukemia and solid cancers) as well as renal complications (chronic renal failure) particularly in patients with renal malformations or a single kidney. The main risk factor affecting event-free survival is the patient's age at the time of transplantation.


Fanconi anemia; Allogeneic hematopoietic stem cell transplantation; Fludarabine; Graft failure; graft-versus-host disease; Hematologic complications


1. L. Torjemane, S. Ladeb, T. Ben Othman, A. Abdelkefi, A. Lakhal, and A. Ben Abdeladhim. Bone Marrow Transplantation from Matched Related Donors for Patients with Fanconi Anemia Using Low-Dose Busulfan and Cyclophosphamide as Conditioning. Pediatr Blood Cancer 2005;46: 496–500.
2. Aker M, Varadi G, Slavin S, et al. Fludarabine-based protocol for human umbilical cord blood transplantation in children with Fanconi anemia. Journal of pediatric hematology/oncology. 1999;21(3):237–9.

Manuscript Submission Information

Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (transplantation@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.

Welcome your submission!